invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline
23-Dec-2021 -
invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it will commence operations on 1 January 2022.
invIOs, a fully owned subsidiary of APEIRON Biologics AG has been assigned APEIRON’s innovative cancer ...
cancer
cancer therapy
cell therapies
+1